Irukulla Shravan Kumar
★    

India,
2014-01-24 09:06
(4141 d 12:46 ago)

Posting: # 12255
Views: 4,572
 

 Haemolysed Samples [Bioanalytics]

Dear,

is there any ipmact of haemolysed samples during the bioanalytical process??. if there what are the necessary actions to be taken.

Kindly address this.

Regards,
I.Shravan


Edit: Category changed. [Helmut]
ElMaestro
★★★

Denmark,
2014-01-24 12:46
(4141 d 09:05 ago)

@ Irukulla Shravan Kumar
Posting: # 12256
Views: 3,688
 

 Haemolysed Samples

Hi ISK,

❝ is there any ipmact of haemolysed samples during the bioanalytical process??. if there what are the necessary actions to be taken.


You probably have a validation report which deals with hemolysis. It will tell you if hemolysis is a big problem or not.
Some might say that all samples are hemolysed to some extent, you can just not always see it. Anyways, if hemolysis suddenly and unexpectedly occurs at high frequency (subjectively more than just here and there at random) then you could escalate, investigate, rectify.
How to do exactly that depends on working procedures and QMS at your facility.

Pass or fail!
ElMaestro
Ohlbe
★★★

France,
2014-01-26 23:57
(4138 d 21:54 ago)

@ Irukulla Shravan Kumar
Posting: # 12272
Views: 3,715
 

 Haemolysed Samples

Dear I. Shavan,

There are actually 2 points to consider:
  • first point: the blood-to-plasma concentration ratio. If your analyte has a very high distribution into the red blood cells, hemolysis will artificially increase the plasma concentrations. See for instance as part of this paper from Gary Emmons and Malcolm Rowland on DBS: 0.5 % hemolysis is sufficient to increase plasma concentrations of tacrolimus by 10 %. This will be true whatever the bioanalytical method you're using. In such a case you need to be particularly cautious to avoid hemolysis during sample collection. Hemolysed samples will have to be flagged and their results may need to be rejected depending on the amount of hemolysis (define it clearly in the protocol). Whole blood may be a better matrix than plasma (whole blood is traditionally used for cyclosporine, for instance);

  • the possible influence of hemolysis on your bioanalytical method. The EMA guideline on bioanalytical method validation asks you to test for differences in matrix effects, but problems with hemolysed samples can be due to other reasons. See for instance this paper from Nicola Hughes et al., or this one from Eugénie-Raphaëlle Bérubé et al.
The problem of hemolysed samples has been discussed at quite a number of workshops over the last few years. See for instance this white paper from the 2011 WRIB meeting. You will find many papers published in Bioanalysis and other journals.

Regards
Ohlbe
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
50 visitors (0 registered, 50 guests [including 9 identified bots]).
Forum time: 22:52 CEST (Europe/Vienna)

Do not worry about your difficulties in mathematics.
I can assure you mine are still greater.    Albert Einstein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5